Hutchmed (china) Share Discussion Threads

[steeplejack] 28/2/2024 11:44

Good results.Little to worry about other than the geopolitically afflicted rating!

[mcmather] 28/2/2024 11:36

Revenue grew 97%...Strengthened cash balance, with $886.3 million at year end (2022: $631.0m)

[mcmather] 27/2/2024 22:22

Results tomorrow.

[mcmather] 22/2/2024 23:42

Looking a bit better. Did we all get a response to emails sent to the co?

[1jat] 08/2/2024 09:33

AZ reporting $44m of orpathys sales.
This would imply $30m revenue for HCM as flat on H1.

[1jat] 06/2/2024 09:26

I know what you mean NoS, having recently semi-retired….fortunately I don’t have to access my holding here for some time…and I have the option of selling in chunks to give to my kids to put into their LISA…..this company still has a lot to give in the next 10-20 years.

As today’s 10% rise shows this can move quickly upwards…but as we know quickly down too…it is barely believable that all the gain associated with the Takeda deal and FDA approval has evaporated.

[nerdofsteel] 03/2/2024 07:36

thankyou 1jat, I do think that I will be buying at some stage, possibly later this year if or when the geo-politics issues subside. This is such a great under valued Company. My specific issue is one of oppoertunity cost here and my problem of effectively dead money and I have a specific timeframe to grow my investment and frankly time will run out!

[lauders] 03/2/2024 00:47

More positive news yesterday and no positive impact on the share price. HCM really are in a rut at the moment. Thought 2024 was going to be better, but still 11 months to go.

[1jat] 02/2/2024 21:06

NoS
I for one will continue to value your thoughts…..as a long term follower of HCM I expect you will keep an eye on it, in case there is a change of tone and fortune - I also expect you will buy back in at some point…

Good luck with your new investments….tell us what you select.

[nerdofsteel] 02/2/2024 13:19

Bareknee - Bitter posts just make it look like you're continually trying to validate your reasons for selling.

Not at all, I was stating the facts as I see them..

[bareknee] 01/2/2024 17:38

Let it go DaveyNerd. For better or worse you've sold up.

Bitter posts just make it look like you're continually trying to validate your reasons for selling. It's like the reverse of the Quindell situation was for you.

Live, learn and move on, but don't give up the day job !

[mcmather] 01/2/2024 09:08

Agree Lauders; to not engage with shareholders and do absolutely nothing given the recent decline, does just smack of apathy, and comes across as a little feeble.

[lauders] 01/2/2024 08:37

It has been stated they don't really "care" about their shareholders mcmather. I suppose your point sort of confirms this, unfortunately.

[mcmather] 01/2/2024 08:31

Shame there wasn't an update of sorts:

"HUTCHMED (China) Limited (“HUTCHMEDR21;) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2023 on Wednesday, February 28, 2024 at 6:30 am Eastern Standard Time (EST) / 11:30 am Greenwich Mean Time (GMT) / 7:30 pm Hong Kong Time (HKT)."

[mcmather] 31/1/2024 22:38

Bleak viewing the decline over the last 12 months

[nerdofsteel] 30/1/2024 15:39

and the share price falls again as usual

[mcmather] 30/1/2024 09:28

Bit more coverage just landed (nothing really more) here:

“Hutchmed celebrates cancer drug approval in hometown of Hong Kong”


And a bit of coverage from last week (23 Jan 2024): “Patients with previously treated metastatic colorectal cancer (CRC) experienced significant improvement in quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) when treated with a combination of Fruzaqla (fruquintinib) with best supportive care when compared with treatment via placebo and best supportive care, according to post hoc analysis findings from the phase 3 FRESCO-2 trial presented at the 2024 Gastrointestinal Cancers Symposium.”

[lauders] 30/1/2024 07:23

Closed down 0.25% so the news managed to claw back some of the earlier losses.

[lauders] 30/1/2024 05:03

Some good news from HCM today.

Hong Kong, Shanghai & Florham Park, NJ — Tuesday, January 30, 2024: HUTCHMED (China) Limited (Nasdaq/AIM:​HCM, HKEX:​13) (“HUTCHMEDR21;) today announces that the marketing approval of ELUNATE® (fruquintinib) by the Pharmacy and Poisons Board of Hong Kong for the treatment of adult patients with previously treated metastatic colorectal cancer (“CRC”). ELUNATE® is a selective oral inhibitor of vascular endothelial growth factor (“VEGF”) receptors -1, -2 and -3, which play a pivotal role in blocking tumor angiogenesis.

Will it be enough to make the share price + for once? Currently DOWN in HK by 1.88%!

[nerdofsteel] 29/1/2024 14:46

"But hcm still irritates you"

not really, I was just posting an observation about geo-politics at play here and yes I have sold, but I may well buy back in if things begin to improve. In the meantime I've made a packet on Nvidia, more in a month than I have being invested in HCM over 7 years...

[1jat] 28/1/2024 18:23

Lauders - I agree with your sentiment but it could be some time in coming… the macro environment is again at play - I read a US congressman has tabled a bill to sanction certain Chinese Biopharma due to links to the China Army….which cannot be helping US investors.

I doubt many investors in smaller pharma are actually expecting/wanting them to transition into self supporting larger pharma cos.

It is not clear what CKHH position is….they seem to be happy to hold and see the company grow - they dont currently need any cash from their stake, this effectively means HCM is not for sale. If the Vodafone/3 deal goes through CKHH will pocket a couple of Billion and have options to sell out in 2-3 years….

I expect there will be M&A within China biopharma soon…..many companies have cash for a couple of years if fund raising becomes more difficult they will have to be sold…HCM may get to self sustainability before this happens which will put them into a stronger position to buy.

[lauders] 27/1/2024 01:52

One thing is for sure. Anyone with funds to invest at these low RSI levels will make some money going forward. Can't stay at these levels forever, surely? Just needs some good news on trials, M&A activity, sales and a rebound should materialize. Down over 20% this year alone!